Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598801 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A3MAPTCCR3SLC6A4 | |
| SCHEMBL3603057 | 0.76 | CYP3A4 (0.51) | MAPTMEN1KMT2A | |
| SCHEMBL918100 | 0.76 | CCR3 (0.63) | SLC6A2SLC6A3CCR3SLC6A4KCNH2 | |
| SCHEMBL17152551 | 0.75 | SLC6A2 (0.68) | SLC6A2SLC6A3MAPTCCR3SLC6A4 | |
| SCHEMBL29342000 | 0.73 | KCNH2 (0.68) | SLC6A2CCR3SLC6A4KCNH2TMEM97 | |
| SCHEMBL13588754 | 0.73 | CCR3 (0.58) | CCR3KCNH2TMEM97SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL6056792 | 0.72 | OPRM1 (0.51) | SLC6A2SLC6A3CCR3SLC6A4SIGMAR1 | |
| SCHEMBL4729475 | 0.72 | POLB (0.71) | KCNH2POLBMEN1KMT2A | |
| SCHEMBL15251810 | 0.72 | ALDH1A1 (0.55) | MEN1KMT2A | |
| SCHEMBL15251696 | 0.72 | ALDH1A1 (0.55) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | SLC6A2 721/4885SLC6A3 2405/4885MAPT 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.